UnknownNot Applicable

Postoperative Analgesia in Laparoscopic Abdominal Surgery After Exparel Via TAP or Local Infiltration

150 participantsStarted 2019-08

Plain-language summary

This study evaluates differences in how administering liposomal bupivacaine via two different methods affects postoperative pain control in laparoscopic abdominal surgery patients. Half the participants will receive liposomal bupivacaine via a transverses abdominis plane block while the other half will receive liposomal bupivacaine via local infiltration.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients scheduled for elective laparoscopic colorectal surgery at UWMC requiring inpatient stay Exclusion Criteria: * Patients on chronic pain mediations equaling or exceeding \> 25 morphine daily equivalents * Patients allergic to bupivacaine * Patients with ASA status IV, V, or VI * Patients unable to consent * Patients that are pregnant * Patients that are incarcerated * Patients receiving procedures in addition to laparoscopic colorectal procedure * Patients on systemic anticoagulation precluding them from regional blocks

What they're measuring

24 hour post operative opioid consumption

Timeframe: 24 hours postoperative

Trial details

NCT IDNCT03927326

SponsorUniversity of Washington

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-07

Contact for this trial

Alan Chang, MD

714-878-0850 achang5@uw.edu

View on ClinicalTrials.gov More Pain, Postoperative trials